Agoracom Blog Home

Posts Tagged ‘Facial Serum’

VIDEO – Isareli-Based Innocan $INNO.ca Global Commercialization Begins. Completes Manufacturing Run In Europe For Premium #CBD Products, Commences Manufacturing For USA Markets $CGC.ca $APHA $OVAT.ca $KHRN.ca

Posted by AGORACOM-JC at 6:29 PM on Tuesday, January 12th, 2021
Innocan-Blog

2020 was a disappointing one for the once euphoric cannabis industry thanks to the fallout of over-hyped and over-financed companies that failed to deliver on a fraction of their promises.  

The year 2000 saw the exact same thing happen to “dot-com” companies that failed in even more spectacular fashion.  Many investors swore off internet stocks forever.  The smart ones waited to see which companies were real … and the rest was history as we saw the birth and growth of internet companies that delivered real value, products and customers.    

The same is about to happen in the Cannabis space in 2021.  With the market estimated to hit $70 Billion over the next few years, there is very little doubt that winners will be created out of companies delivering real businesses  

Enter Innocan Pharma Corporation (INNO:CSE) (IP4: FSE) and it’s incredible team of accomplished scientists led by CEO Iris Bincovich.   

With Distribution and Manufacturing Agreements already in place for Both Europe and USA, $INNO is now on the verge of Commercializing It’s Clinically Proven CBD Products around the world in 2021.

As a Cannabis investor, why limit yourself to a Company with just one specialty, when InnoCan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products.  

If you believe in the future of the cannabis industry and companies delivering real, value-add CBD products, then watch this interview with Innocan CEO, Iris Bincovich.

Innocan Pharma $INNO.ca Announces the Launch of Its Commercial Website $CGC.ca $APHA $OVAT.ca $KHRN.ca

Posted by AGORACOM-JC at 11:54 AM on Tuesday, January 5th, 2021
Innocan-Blog
  • Announced the launch of its commercial web-platform, shop.innocanpharma.com.
  • The Company, through its wholly owned subsidiary, Innocan Pharma Ltd., has signed certain agreements with world leading companies for the fulfillment, logistics, and service of the website
  • The new website has been designed to offer a user-friendly experience with excellent navigation and functionality, allowing consumers to see the full product information to enhance the shopping experience

Herzliya, Israel and Calgary, Alberta–(January 5, 2021) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the “Company” or “Innocan“), is pleased to announce the launch of its commercial web-platform, shop.innocanpharma.com. The Company, through its wholly owned subsidiary, Innocan Pharma Ltd. (“Innocan Israel”), has signed certain agreements with world leading companies for the fulfillment, logistics, and service of the website. The new website has been designed to offer a user-friendly experience with excellent navigation and functionality, allowing consumers to see the full product information to enhance the shopping experience.

The online product distribution will be led and handled by Brandzon Co Ltd. (www.brandzon.co), a company which specializes in ecommerce growth and worldwide acceleration. The Brandzon team has a proven sales track record worldwide, with global 3PL (Third-Party-Logistics) capabilities.

Roni Kamhi, CEO & Co-founder of Brandzon said, “We believe that Innocan is a leading innovative pharmaceutical company that has the potential to bring an advanced formulated product into the skincare market with the science to back it. Together we can achieve success in the ecommerce space and generate revenue for both companies.”



Innocan Pharma products

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6922/71307_6574846314346977_002full.jpg

“We are pleased to unveil our new website shop.innocanpharma.com,” says Iris Bincovich, founder and CEO of Innocan Pharma. “The site will allow consumers to browse smoothly through our product collection and find the perfect product that will meet their requirements. This is a major milestone and a great opportunity for Innocan to start with B2C operation that will secure a new and sustainable source of income for the Company.”

About Innocan

The Company, through Innocan Israel, is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol (“CBD“). Innocan Israel and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the COVID-19 coronavirus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholtz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Innocan $INNO.ca Pharma Announces Closing of Private Placement $CGC.ca $APHA $OVAT.ca $KHRN.ca

Posted by AGORACOM-JC at 8:41 AM on Thursday, December 31st, 2020
Innocan-Blog
  • Announced that it has today closed a non-brokered private placement offering of 10,294,800 units of Innocan at a price of $0.23 per Units for aggregate gross proceeds of $2,367,804
  • All Common Shares and Warrants issued pursuant to the Offering will be subject to a four month statutory hold period commencing from the closing date under applicable securities laws.

Herzliya, Israel and Calgary, Alberta–(December 31, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the “Company” or “Innocan”) is pleased to announce that it has today closed a non-brokered private placement offering of 10,294,800 units of Innocan (the “Units”) at a price of $0.23 per Units for aggregate gross proceeds of $2,367,804 (the “Offering”).

All Common Shares and Warrants issued pursuant to the Offering will be subject to a four month statutory hold period commencing from the closing date under applicable securities laws.

Each Unit consists of one common share in the capital of the Company (“Common Share”) and one-half of one common share purchase warrant (“Warrant”). Each whole Warrant entitles the holder to purchase one Common Share at a price of $0.35 for a period of three years from the date of issuance.

Following the date of issuance of the Warrants, if the daily volume weighted average trading price of the Common Shares on the Canadian Securities Exchange for any period of 30 consecutive trading days equals or exceeds $0.70, the Company may, upon providing written notice to the holders of the Warrants (the “Acceleration Notice”), accelerate the expiry date of the Warrants to the date that is 30 days following the date of the Acceleration Notice.

Innocan intends to use the proceeds of the Offering for general working capital and corporate purposes.

“Our investors continue to show confidence in the Company. We are delighted to complete this private placement” stated Iris Bincovich, Chief Executive Officer of Innocan. “Despite the holiday season and the four months hold period that applies to the Units”.

About Innocan

The Company, through its wholly owned Israeli subsidiary, Innocan Pharma Ltd. (“Innocan Israel”), is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol (“CBD“). Innocan Israel and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Coronavirus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholtz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Innocan Pharma $INNO.ca Announces the Successful Completion of Its First Full-Scale Manufacturing Run in Europe and the Commencement of Its Full-Scale Manufacturing Run in the USA $CGC.ca $APHA $OVAT.ca $KHRN.ca

Posted by AGORACOM-JC at 4:13 PM on Wednesday, December 16th, 2020
Innocan-Blog
  • Announced the completion of its first commercial production of the Shir premium cosmetic line and Relief & Go topicals in Portugal and is pleased to announce the commencement of production in the United States, for the first time
  • Innocan has successfully completed its first commercial manufacturing run of in Europe/Portugal and will commence a first manufacturing run in North America.
  • In Portugal, InnoCan has now a storage of 35,000 Units of our SHIR™ and Relief & Go™ line and will commence a first manufacturing run in North America, effective immediately to manufacture an initial stock of 40.000 units.
  • These production activities will enable the Company to deliver product to the European and US markets accordingly.

Herzliya, Israel and Calgary, Alberta–(December 16, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the “Company” or “Innocan”), is pleased to announce the completion of its first commercial production of the Shir premium cosmetic line and Relief & Go topicals in Portugal and is pleased to announce the commencement of production in the United States, for the first time.

Innocan has successfully completed its first commercial manufacturing run of in Europe/Portugal and will commence a first manufacturing run in North America. In Portugal, InnoCan has now a storage of 35,000 Units of our SHIR™ and Relief & Go™ line and will commence a first manufacturing run in North America, effective immediately to manufacture an initial stock of 40.000 units. These production activities will enable the Company to deliver product to the European and US markets accordingly.



Figure 1

To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/6922/70446_4fe15a788442696d_002full.jpg

Innocan sees this manufacturing advance as a major milestone in the Company’s commercialization, while maintaining a consistent and high-quality product. Innocan’s next step will be to produce additional inventory to service the Company’s expansion into the U.S. market as it rapidly expands into retail distribution and scales its online sales.

“We are moved by the immense and positive market-response to our long awaited product launch and are pleased to have the ability to increase our inventory following the demand demonstrated by our SHIR and R&G product lines,” said Iris Bincovich, CEO and Co-Founder of Innocan Pharma.

About Innocan

The Company, through its wholly owned Israeli subsidiary, Innocan Pharma Ltd. (“Innocan Israel”), is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol (“CBD“). Innocan Israel and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the COVID-19 Coronavirus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholtz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Innocan Pharma $INNO.ca Completes Its Trademark Registration in the EU, UK and Switzerland $CGC.ca $APHA $OVAT.ca $KHRN.ca

Posted by AGORACOM-JC at 4:09 PM on Thursday, December 10th, 2020
Innocan-Blog
  • Announced the completion of the registration of its trademarks: Innocan Pharma, Relief & Go and SHIR in the EU, UK and Switzerland.
  • These trademarks represent Innocan’s OTC and derma cosmetic brand products that were recently launched in the German and UK markets.

Herzliya, Israel and Calgary, Alberta–(December 10, 2020) –  Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the “Company” or “Innocan“), is pleased to announce the completion of the registration of its trademarks: Innocan Pharma, Relief & Go and SHIR in the EU, UK and Switzerland. These trademarks represent Innocan’s OTC and derma cosmetic brand products that were recently launched in the German and UK markets.

Figure 1

To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/6922/69990_4005126294fb3804_002full.jpg

“We are excited to have a Registered Trademark for our Brands in time to allow us to initiate the sales effort in the EU, UK and Switzerland,” says Iris Bincovich, Founder and CEO of Innocan, “This is another way that we have added value to the Company that will be recognized in 2021.”

www.facebook.com/Innocanpharma

https://www.instagram.com/theinnocanpharma/

About Innocan

The Company, through its wholly owned Israeli subsidiary, Innocan Pharma Ltd. (“Innocan Israel”), is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol (“CBD“). Innocan Israel and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the COVID-19 Corona Virus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholtz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

AGORACOM Small Cap 60: Innocan $INNO.ca Developing The Pharmaceutical Guided Missile To Defeat #Coronavirus Lung Infections $CGC.ca $APHA $OVAT.ca $KHRN.ca

Posted by AGORACOM-JC at 12:53 PM on Friday, November 27th, 2020
Innocan-Blog

Innocan Pharma Corporation (INNO:CSE) (IP4:FSE) has 3 fully operating divisions to address the market for Cannabis products.  As a Cannabis investor, why limit yourself to a Company with just one specialty, when InnoCan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products.

Innocan Pharma $INNO.ca Provides Significant Update On Injectable #CBD Delivery System Program $CGC.ca $APHA $OVAT.ca $KHRN.ca

Posted by AGORACOM-JC at 2:58 PM on Monday, November 23rd, 2020
Innocan-Blog
https://youtu.be/CBP9fkwiaV0

Innocan Pharma (CSE: INNO) CEO Iris Bincovich joined Steve Darling from Proactive with news the company has provided an update on their Injectable CBD delivery system that allows control release.

Bincovich telling Proactive some of the recent works done to prove the efficacy of the project and also a bit of detail of the man leading the project, Prof Chezy Barenholz from the Hebrew University.

Source: https://ca.proactiveinvestors.com/companies/news/934691/innocan-pharma-bring-significant-update-on-injectable-cbd-delivery-system-program-934691.html

VIDEO – Isareli-Based Innocan $INNO.ca Distribution and Manufacturing Agreements, In Both Europe and USA, Point To Commercialization Of Clinically Proven #CBD Products In 2021 $CGC.ca $APHA $OVAT.ca $KHRN.ca

Posted by AGORACOM-JC at 5:16 PM on Thursday, November 19th, 2020
Innocan-Blog

2020 has been a disappointing one for the once euphoric cannabis industry thanks to the fallout of over-hyped and over-financed companies that failed to deliver on a fraction of their promises.  

The year 2000 saw the exact same thing happen to “dot-com” companies that failed in even more spectacular fashion.  Many investors swore off internet stocks forever. 

The smart ones waited to see which companies were real … and the rest was history as we saw the birth and growth of internet companies that delivered real value, products and customers.    

The same is about to happen in the Cannabis space.  With the market estimated to hit $70 Billion over the next few years, there is very little doubt that winners will be created out of companies delivering real businesses.

Enter Innocan Pharma Corporation (INNO:CSE) (IP4: FSE) and it’s incredible team of accomplished scientists led by CEO Iris Bincovich.  

As a Cannabis investor, why limit yourself to a Company with just one specialty, when InnoCan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products, the latter of which have already announced distribution and manufacturing agreements throughout Europe and the United States.

If you believe in the future of the cannabis and companies delivering real, value-add CBD products, then watch this interview with Innocan CEO, Iris Bincovich.

EVENT: CSE Presents Tech Tuesdays: Israeli Technology Advancements Featuring InnoCan Pharma $INNO.ca $CGC.ca $APHA $OVAT.ca $KHRN.ca

Posted by AGORACOM-JC at 7:37 AM on Tuesday, November 17th, 2020
Innocan-Blog

Don’t Miss Tech Tuesdays: Israeli Technology Advancements

The CSE looks forward to co-hosting our next Tech Tuesdays showcase, Israeli Technology Advancements, with the Canada Israel Chamber of Commerce

Join us live on November 17th!

Check out the exciting list of featured speakers! 

Don’t miss out on this exclusive glimpse at the cutting-edge technologies hailing from Israel that are making waves internationally. 

Innocan $INNO.ca Moves to an Advanced Efficacy Trial on Animals of Its Liposome-CBD Injection, Following Encouraging Results on the First Stage $CGC.ca $APHA $OVAT.ca $KHRN.ca

Posted by AGORACOM-JC at 7:58 AM on Monday, November 16th, 2020
Innocan-Blog
  • Announced today the launch of two therapeutic studies on small and large animals examining the therapeutic efficacy of Innocan’s CBD loaded liposome platform technology (“LPT”) in relevant diseases
  • These studies follow the results of previous studies which demonstrated the prolonged release of Cannabidiol for at least 3 weeks into the blood of mice and rats after a single injection
  • The new studies will be conducted by the Hebrew University of Jerusalem

Herzliya, Israel and Calgary, Alberta–(November 16, 2020) –  Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce today the launch of two therapeutic studies on small and large animals examining the therapeutic efficacy of Innocan’s CBD loaded liposome platform technology (“LPT”) in relevant diseases. These studies follow the results of previous studies which demonstrated the prolonged release of Cannabidiol for at least 3 weeks into the blood of mice and rats after a single injection. The new studies will be conducted by the Hebrew University of Jerusalem.

The original study which was led by Dr. Ahuva Cern, Senior Researcher in the lab of Prof. Barenholz at the Hebrew University in Jerusalem found significant amounts of CBD in mices’ blood and muscles up to 21 days after they were injected intramuscular with a single injection of CBD using LPT. The same findings were also demonstrated in rats.

These results are substantial when compared to oral or smoking administration of CBD, in which CBD was found in the blood only for a period of up to 36 hours after one administration.

The results of this study may indicate that Innocan’s LPT, with an injection only once or twice a month, may relieve pain or other symptoms when using CBD. These results may open the door for future experiments to prove a lack of toxicity and therapeutic efficacy of this formulation.

Innocan Israel, a wholly owned subsidiary of Innocan, has entered into a worldwide exclusive research and license agreement with Yissum Research and Development Company (“Yissum“), the commercial arm of the Hebrew University of Jerusalem in Israel, in respect of the design, preparation, characterization and evaluation of hydrogels containing CBD (or other cannabinoid) loaded liposomes. The development is led by Prof. Chezy Barenholz, head of the Membrane and Liposome department at the Hebrew University, who invented over 55 patent families, two of which underlie Doxil – the first FDA approved nano-drug aim for cancer treatment. This LPT unique technology platform may be effective for several applications (such as epilepsy, pain relief, and different inflammation and central nervous system disorders). A patent was filed by Innocan Israel on the LPT technology on October 7, 2019.

Prof. Chezy Berenholz, head of the Laboratory of Membrane and Liposome Research of the Hebrew University stated: ” I believe that these additional animal and efficacy studies are extremely important and may result in a major milestone. This may open a wide range of clinical applications, while maintaining the CBD level in the blood for a long period of time which may lead to better patient compliance. If successful, the technology may be beneficial for various indications”.

About Innocan

The Company, is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD. Innocan Israel and Ramot at Tel Aviv University, are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholz Head of the Laboratory of Membrane and Liposome Research of the Hebrew University, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for the relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Israel have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.